New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Cole Werble
Washington, DC
Cole Werble is the former owner and editorial director of FDC Reports, Inc., the publisher of The Pink Sheet, The Gray Sheet, and other leading news publications for the health care industry. He has more than 35 years of experience analyzing business critical developments affecting the biopharma sector and developing world class information products for the sector.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cole Werble
Benefit-Risk Math: US FDA Still Favors Simple Calculations
A core group of big pharma companies has been pressing FDA for over a decade to adopt a quantitative formula for conducting and communicating benefit-risk decisions. FDA has changed its benefit-risk calculations in response – but not its basic way of doing the math.
US FDA “Enriches” Trial Guidance With Recent Examples
Illustrating that principles articulated in 2012 draft are being broadly accepted at FDA, final guidance on enrichment strategies for clinical trials adds new examples from across the agency’s drug review divisions.
Gilead Has Full HIV Policy Agenda For 2019: Part D Challenge; Prophylaxis Increase
Gilead faces two-pronged policy challenge in its core HIV business: its Part D product line could lose protections, but prophylactic prescriptions could dramatically expand under the Trump Administration's plan to eliminate HIV transmission.
FDA’s Sentinel Strategy: Starting Slow Move Toward “Active” Surveillance
US FDA’s strategic plan for Sentinel includes pilot projects to move towards the vision of active surveillance. However, FDA is also making clear that it won’t be a quick or easy transformation.
Civica Rx's Strategy To Reduce Drug Shortages Focuses On Guaranteed-Price Contracts
Non-profit intermediary being built by hospitals and health systems offers a private sector response to one of the deterrents to adequate supplies of important older generic drugs.
Counter-Intuitive Thinking To Combat Drug Shortages
Search for solutions to chronic drug shortages may require policymakers to push for payment policies that run counter to the current drug pricing themes, like retrofitting US Medicare’s New Technology Add-On Payments to apply to old, off-patent therapies.
Advertisement